
A study evaluated critical immune system components to predict severe COVID-19 in CVD patients and found that infected CVD patients had more activated monocyte subsets, mature natural killer cells, plasmablasts, and CD4+ central memory T cells but fewer innate lymphoid cells, CD8+ T-cell subsets, CD16+ monocytes, and dendritic cells. An immune signature characterized by a low frequency of mucosal-associated invariant T cells and intermediate effector CD8+ T-cells, as well as a high frequency of natural killer T cells, was identified and could be used to differentiate between high-risk CVD patients experiencing mild or severe COVID-19. Ultimately, these findings could help prevent long-term ICU admission or death in CVD patients with COVID-19.
Like
Save
Share